FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387410326> ?p ?o ?g. }

• W4387410326 endingPage "e116" @default.
• W4387410326 startingPage "e116" @default.
• W4387410326 abstract "Aromatase inhibitors (AI) are recommended for patients with known estrogen receptor (ER) positive cancer (for example, ER+ breast cancer) during ovarian stimulation (OS) for fertility preservation. However, other tumor types may be estrogen responsive and thus benefit from AI therapy during fertility preservation. The objectives of our study were (1) to estimate estrogen responsiveness of various tumor types using The Cancer Genome Atlas (TCGA) to determine ER-alpha (ERa) gene expression, and (2) to investigate molecular subtypes of breast cancer, ER negative by immunohistochemistry, which still express ERa. We hypothesize that ER- breast tumors are heterogenous, and some may still express ERa and benefit from AI during OS. TCGA Pan-Cancer Atlas gene expression data were accessed from UCSC Xena browser; data included >30 primary tumor types from almost 6,000 female patients. Tumors were ranked by average ERa gene expression. A secondary analysis included tumors from only ∼1K females aged 13-44, to represent a population that may undergo fertility preservation with OS. Next, we investigated ERa expression in 459 ER negative (ER-, as determined by immunohistochemistry) breast tumor samples obtained from Molecular Taxonomy of Breast Cancer International Consortium (METABRIC). We computed the average expression of ERa in all molecular subtypes of breast cancer (luminal A, luminal B, Her2 enriched and basal) from the METABRIC cohort. ERa was expressed in nearly all tumor types. ERa expression was highest in breast tumors and lowest in rectal adenocarcinomas in all female patients. The top five tumor types with highest ERa expression included breast, uterine/endometrial, ovarian, cervical, and thyroid tumors. In females aged 13-44, endometrial carcinomas have the highest ERa expression followed by ovarian and breast tumors. ERa expression in breast tumors is very subtype-specific, and some ER- tumors expressed ERa. ERa was relatively highly expressed in ER- luminal breast tumors as compared with basal tumors. Breast, uterine/endometrial, cervical, and thyroid tumors, among others, appear to be estrogen-responsive and may benefit from AI therapy for estrogen blockade during OS for fertility preservation.Even some ER-breast tumors express ERa. Further clinical studies will be necessary to assess the significance of ERa gene expression in determining the benefits of AI during OS." @default.
• W4387410326 created "2023-10-07" @default.
• W4387410326 creator A5014172429 @default.
• W4387410326 creator A5030432328 @default.
• W4387410326 creator A5049567745 @default.
• W4387410326 creator A5059588919 @default.
• W4387410326 date "2023-10-01" @default.
• W4387410326 modified "2023-10-08" @default.
• W4387410326 title "WHICH PATIENTS NEED AROMATASE INHIBITORS DURING OVARIAN STIMULATION FOR FERTILITY PRESERVATION? ER-ALPHA EXPRESSION AS A SURROGATE FOR ESTROGEN RESPONSIVENESS" @default.
• W4387410326 doi "https://doi.org/10.1016/j.fertnstert.2023.08.373" @default.
• W4387410326 hasPublicationYear "2023" @default.
• W4387410326 type Work @default.
• W4387410326 citedByCount "0" @default.
• W4387410326 crossrefType "journal-article" @default.
• W4387410326 hasAuthorship W4387410326A5014172429 @default.
• W4387410326 hasAuthorship W4387410326A5030432328 @default.
• W4387410326 hasAuthorship W4387410326A5049567745 @default.
• W4387410326 hasAuthorship W4387410326A5059588919 @default.
• W4387410326 hasConcept C121608353 @default.
• W4387410326 hasConcept C126322002 @default.
• W4387410326 hasConcept C143998085 @default.
• W4387410326 hasConcept C172313692 @default.
• W4387410326 hasConcept C204232928 @default.
• W4387410326 hasConcept C2776166826 @default.
• W4387410326 hasConcept C2777164284 @default.
• W4387410326 hasConcept C2777904497 @default.
• W4387410326 hasConcept C2908647359 @default.
• W4387410326 hasConcept C29456083 @default.
• W4387410326 hasConcept C502942594 @default.
• W4387410326 hasConcept C518429986 @default.
• W4387410326 hasConcept C530470458 @default.
• W4387410326 hasConcept C71924100 @default.
• W4387410326 hasConcept C84606932 @default.
• W4387410326 hasConcept C86803240 @default.
• W4387410326 hasConcept C99454951 @default.
• W4387410326 hasConceptScore W4387410326C121608353 @default.
• W4387410326 hasConceptScore W4387410326C126322002 @default.
• W4387410326 hasConceptScore W4387410326C143998085 @default.
• W4387410326 hasConceptScore W4387410326C172313692 @default.
• W4387410326 hasConceptScore W4387410326C204232928 @default.
• W4387410326 hasConceptScore W4387410326C2776166826 @default.
• W4387410326 hasConceptScore W4387410326C2777164284 @default.
• W4387410326 hasConceptScore W4387410326C2777904497 @default.
• W4387410326 hasConceptScore W4387410326C2908647359 @default.
• W4387410326 hasConceptScore W4387410326C29456083 @default.
• W4387410326 hasConceptScore W4387410326C502942594 @default.
• W4387410326 hasConceptScore W4387410326C518429986 @default.
• W4387410326 hasConceptScore W4387410326C530470458 @default.
• W4387410326 hasConceptScore W4387410326C71924100 @default.
• W4387410326 hasConceptScore W4387410326C84606932 @default.
• W4387410326 hasConceptScore W4387410326C86803240 @default.
• W4387410326 hasConceptScore W4387410326C99454951 @default.
• W4387410326 hasIssue "4" @default.
• W4387410326 hasLocation W43874103261 @default.
• W4387410326 hasOpenAccess W4387410326 @default.
• W4387410326 hasPrimaryLocation W43874103261 @default.
• W4387410326 hasRelatedWork W1982850748 @default.
• W4387410326 hasRelatedWork W2004151698 @default.
• W4387410326 hasRelatedWork W200925908 @default.
• W4387410326 hasRelatedWork W2087504465 @default.
• W4387410326 hasRelatedWork W2089744500 @default.
• W4387410326 hasRelatedWork W2117019370 @default.
• W4387410326 hasRelatedWork W2335928397 @default.
• W4387410326 hasRelatedWork W2364285896 @default.
• W4387410326 hasRelatedWork W3010551324 @default.
• W4387410326 hasRelatedWork W3209895153 @default.
• W4387410326 hasVolume "120" @default.
• W4387410326 isParatext "false" @default.
• W4387410326 isRetracted "false" @default.
• W4387410326 workType "article" @default.